Media stories about Hologic (NASDAQ:HOLX) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Hologic earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave news stories about the medical equipment provider an impact score of 46.1797068780391 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have effected Accern Sentiment’s rankings:
- Hologic Looks Iffy For Now (seekingalpha.com)
- *Hologic INC (HOLX) Position Held by Stoneridge Investment Partners Llc (thecasualsmart.com)
- Financial Comparison: Check Cap (CHEK) vs. Hologic (HOLX) (americanbankingnews.com)
- Stoneridge Investment Partners LLC Cut Its Hologic INC (HOLX) Position by $3.43 Million; Market Valuation Declined (styleonfleek365.com)
- Analyzing Hologic (HOLX) & Check Cap (CHEK) (americanbankingnews.com)
A number of research analysts have issued reports on HOLX shares. Bank of America raised shares of Hologic from a “neutral” rating to a “buy” rating and set a $50.00 price target for the company in a report on Thursday, January 4th. Goldman Sachs cut shares of Hologic from a “conviction-buy” rating to a “buy” rating and set a $43.00 price target for the company. in a report on Monday, March 26th. Zacks Investment Research cut shares of Hologic from a “buy” rating to a “hold” rating in a report on Tuesday, March 6th. Cowen raised shares of Hologic to a “buy” rating and set a $52.00 price target for the company in a report on Wednesday, December 20th. Finally, Deutsche Bank cut shares of Hologic from a “buy” rating to a “hold” rating and set a $49.00 price target for the company. in a report on Friday, January 19th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and nine have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $47.21.
Hologic (NASDAQ:HOLX) last issued its earnings results on Thursday, February 8th. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.05. Hologic had a net margin of 34.53% and a return on equity of 20.07%. The firm had revenue of $791.10 million during the quarter, compared to analysts’ expectations of $785.80 million. During the same quarter last year, the company posted $0.52 earnings per share. The firm’s revenue was up 7.7% compared to the same quarter last year. equities analysts expect that Hologic will post 2.25 EPS for the current year.
In other Hologic news, Director Namal Nawana bought 6,600 shares of Hologic stock in a transaction that occurred on Tuesday, February 13th. The stock was purchased at an average price of $37.88 per share, with a total value of $250,008.00. Following the completion of the acquisition, the director now directly owns 6,954 shares in the company, valued at approximately $263,417.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Allison P. Bebo sold 7,000 shares of the firm’s stock in a transaction on Friday, March 16th. The stock was sold at an average price of $38.75, for a total transaction of $271,250.00. The disclosure for this sale can be found here. Company insiders own 0.79% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This story was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.tickerreport.com/banking-finance/3341941/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-hologic-holx-stock-price.html.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.